Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT05751928

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.

Sponsor: Biocad

Conditions Melanoma (Skin) Melanoma Stage III

Interventions BCD-217 Excision of the primary lesion Regional lymphadenectomy anti-PD1

Updated 6 times since 2023 Last updated: Jul 7, 2025 Started: Apr 5, 2023 Primary completion: Jan 31, 2027 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Melanoma (Skin) and Melanoma Stage III, this trial is ongoing. The trial is conducted by Biocad and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2024 — Aug 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Apr 2023 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biocad

Data source: Biocad

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chelyabinsk, Russia , Gatchina, Russia , Kazan', Russia , Kemerovo, Russia , Kostroma, Russia , Krasnodar, Russia , Kuz'molovskiy, Russia , Lesnoy, Belarus , Minsk, Belarus , Mogilev, Belarus and 11 more locations